Jemperli fachinfo
WebAug 17, 2024 · JEMPERLI is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced: endometrial cancer (EC), as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen, or WebApr 12, 2024 · 今年2月，美国食品药品监督管理局（FDA）已常规批准Jemperli（dostarlimab，中文名：多塔利单抗）用于治疗复发或晚期子宫内膜癌的患 …
Jemperli fachinfo
Did you know?
WebApr 22, 2024 · About JEMPERLI (dostarlimab-gxly) JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2 [viii]. In addition to GARNET, JEMPERLI is being investigated in other registrational enabling studies, as monotherapy and as part of … WebApr 23, 2024 · JEMPERLI is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability‑high (MSI‑H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum‑containing regimen. Immune-Mediated Adverse Reactions
WebApr 22, 2024 · JEMPERLI was generated by AnaptysBio using its proprietary somatic hypermutation (SHM) antibody platform and subsequently developed by TESARO, Inc., now a part of GSK, under a collaboration agreement.
WebFeb 1, 2024 · Jemperli is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or PD-ligand 1 (PD-L1), blocking the PD … WebNov 21, 2024 · JEMPERLI 500 mg concentrate for solution for infusion Active Ingredient: dostarlimab Company: GlaxoSmithKline UK See contact details ATC code: L01XC40 About Medicine Prescription only medicine Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Live Chat This information is for use by healthcare professionals
WebJEMPERLI can cause immune-mediated hepatitis, which can be fatal. Grade 3 hepatitis occurred in 0.5% (3/605) of patients. Adrenal Insufficiency. Adrenal insufficiency occurred in 1.2% (7/605) of patients, including Grade 2 (0.5%) and Grade 3 (0.7%). For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment per institutional ...
WebTaking JEMPERLI Your JEMPERLI intravenous infusion will be APPROXIMATELY 30 MINUTES FIRST 4 DOSES EVERY 3 WEEKS THEN EVERY 6 WEEKS Visits for your infusion … cry\u0027s partner crosswordWebJEMPERLI (dostarlimab for injection) January 31, 2024 6Page of 34 • Subsequent dosing beginning 3 weeks after Dose 4 (Dose 5 onwards): 1,000 mg every 6 weeks The dosage … cry\\u0027s partner crossword clueWebJEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced : … dynamics mvpWebJEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody • Infusion-related reactions: Interrupt, slow the rate of infusion, or indicated for the treatment of adult … dynamics music worksheetWebFeb 26, 2024 · The full indication is: Jemperli is indicated as monotherapy for the treatment of adult patients with recurrent or advanced dMMR/MSI-H endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. Jemperli must be initiated and supervised by specialist physicians experienced in the treatment of … cry\u0027s partner crossword clueWebThe recommended dosage of JEMPERLI is: • Dose 1 through Dose 4: 500 mg every 3 weeks • Subsequent dosing beginning 3 weeks after Dose 4 (Dose 5 onwards): 1,000 mg every 6 weeks Administer JEMPERLI as an intravenous infusion over 30 minutes. Treat patients until disease progression or unacceptable toxicity. cry\u0027s partner in phrase crosswordWebApr 22, 2024 · Jemperli can cause serious conditions known as immune-mediated side effects, including inflammation of healthy organs such as the lungs (pneumonitis), colon … dynamic smx 800 turbo